This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Herbut, P. A. Articles by Kraemer, W. H. Search for Related Content PubMed PubMed Citation Articles by Herbut, P. A. Articles by Kraemer, W. H.

The Effect of N,N'-(4-methyl-m-phenylene)-bis(aziridinecarboxamide) (ESK 230) on Walker Mammary Carcinoma 256

( Elizabeth Storck Kraemer Memorial Foundation and Department of Pathology, Jefferson Medical College and Hospital, Philadelphia, Pennsylvania)

The administration of 0.4 mg. of N,N'-(4-methyl-m-phenylene)-bis(aziridinecarboxamide)/100 gm body weight intraperitoneally 3 times weekly to 100 rats of the Sprague-Dawley strain bearing the transplantable Walker mammary carcinoma 256 produced complete regression of tumor in 68 animals and a favorable response in 31 others, giving a total salutary effect of 99 per cent. Of 85 animals treated with 0.25 cc. of physiologic saline/100 gm body weight intraperitoneally daily, four showed complete regression of tumor, and none showed a favorable response, giving a total salutary effect of 4.7 per cent. Of 66 animals treated with 0.4 mg triethylene melamine/100 gm body weight by stomach tube once weekly, 41 disclosed complete regression of tumor, and nine disclosed a favorable response, giving a total salutary effect of 75.8 per cent. Under the conditions of this experiment it is concluded that N,N'-(4-methyl-m-phenylene)-bis(aziridinecarboxamide) is a better tumor-inhibitor than is triethylene melamine. Administered by stomach tube, however, the total necessary dose of N,N'-(4-methyl-m-phenylene)-bis(aziridinecarboxamide) is 25 times that of triethylene melamine, and its effectiveness is greatly reduced.

Received 5/16/55.